Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Konar, you should perhaps rein in your arrogance for a moment. I think most people investing in equities are competent enough to read the date on an article. It is however relevant and worthy of discussion without the snide comment from you.
Many new investors are not up to speed with Scancell.
I did put a comment at the bottom ( in case anyone has not seen this.)
Many informed and knowledgeable people are put off bothering with discussion boards because of such behaviour.
I would have appreciated some reply re the latest Keytruda data in Melanoma relevant to Scib 1 instead of your childish antics.
Scancell is calling for more funding to progress its new vaccine through clinical trial - hoping for a large pharmaceutical partner and investment of hundreds of millions of pounds.
Dr O'Bryan-Tear was optimistic the vaccine could be developed within a year - pointing to a similar timeframe for the first Covid jabs.
He said: "There is no reason why, if we get a partner, we shouldn't be able to do it as quickly as the others have done it."
The doctor added: "I think the pandemic will be around for two or three more years, because of supply, because of not being able to vaccinate developing countries.
"During that time, the virus will mutate, so there are plenty of opportunities for new entrants to try their hand.”
https://www.thesun.co.uk/news/14041135/universal-vaccine-beat-all-covid-strains/
32 minutes ( in case anyone has not seen this.)
https://vimeo.com/497956903
@DeItaone
·
14m
COVID: PUBLIC HEALTH ENGLAND SAYS SOME PRELIMINARY LAB EVIDENCE SUGGESTS B.1.621 VARIANT MIGHT LEAD TO SOME EVASION OF VACCINE OR NATURALLY DERIVED IMMUNITY
COVID: PUBLIC HEALTH ENGLAND SAYS INITIAL FINDINGS INDICATE THAT LEVELS OF VIRUS IN THOSE WHO BECOME INFECTED WITH DELTA BUT HAVE ALREADY BEEN VACCINATED MAY BE SIMILAR TO LEVELS FOUND IN UNVACCINATED PEOPLE
Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial
US FDA Grants Priority Review to Merck’s Application for KEYTRUDA Based on These Data
https://www.businesswire.com/news/home/20210805005406/en/Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Significantly-Prolonged-Recurrence-Free-Survival-RFS-Compared-to-Placebo-as-Adjuvant-Therapy-for-Patients-With-Stage-II-Resected-High-Risk-Melanoma-in-Phase-3-KEYNOTE-716-Trial
Scancell’s Phase 2 clinical study of SCIB1 in late-stage melanoma patients receiving Keytruda® as standard of care [NCT04079166].
Bayer AG agreed to buy U.S. biotech company Vividion Therapeutics Inc. for as much as $2 billion, snapping up a developer of promising therapies that only weeks ago filed for an initial public offering.
https://www.bloomberg.com/news/articles/2021-08-05/bayer-to-buy-vividion-therapeutics-for-up-to-2-billion
https://vividion.com/our-pipeline/
Immunitybio AAV targeting s & n
https://immunitybio.com/pipeline/
Mkt cap 4.24B
Prev close 11.27
52-wk high 45.42
emerge as a problem. “Multiple boosting for these virally-vectored vaccines will be limited by progressive boosting of anti-vector immunity and new variant adenovirus-based vaccines may not be feasible due to pre-existing vector immunity that is likely to abrogate responses against any new insertion.
DNA vaccines could also provide large-scale, low cost manufacture, with long-term stability and no need for ultra-cold storage, the company adds.
https://www.biopharma-reporter.com/Article/2021/08/02/Could-DNA-based-COVID-19-vaccine-offer-variant-busting-booster-shot
4 Aug '21 - 10:45 - 73 of 76 Edit
0 2 0
mRNA is a hot area with Big Pharma illustrated by Sanofi`s purchase of Translate Bio for $3.2bn yesterday.
"relatively cheap compared with many of the other mRNA players, and there is a growing belief that this technology will be the next big thing in vaccines, and not just those for Covid-19. The deal will make Sanofi the only large vaccine player with a wholly owned mRNA platform in house. With Translate now off the scene, Arcturus Therapeutics, with a market cap of around $900m, now looks like the only affordable mRNA player. Given the potential advantages of mRNA vaccines over traditional approaches, arguably any vaccine player without mRNA technology risks getting left behind but the question now is whether impressive results in Covid-19 will translate across other infectious diseases, and indeed whether mRNA can move into areas such as oncology, which is surely where big money lies. "
HTTPS://www.evaluate.com/vantage/articles/news/deals/sanofi-translates-its-mrna-interest-big-bucks
Scancell is currently under the radar of investors, maybe not Biontech and a few others?
DNA advantages over mRNA;
mRNA vaccines can only incorporate a single antigen – the inclusion of two antigens would require the development of a second, separate mRNA vaccine. DNA vaccines such as COVIDITY can accommodate multiple antigens in the same vaccine
Scancell has solved issues common with DNA vaccines;
The key design features of an ImmunBody® vaccine include:
Epitopes that bind to both MHC class I (for the cytotoxic CD8 Tc cell response) and MHC class II (for the helper CD4 Th cell response);
Inclusion of motifs (e.g., GC rich regions) to ensure it is immunogenic and that it is taken up directly by dendritic cells;
Retention of the Fc region of the protein form of the ImmunoBody® which targets activated dendritic cells via its specific receptor.
The most important aspect of the ImmunoBody® technology is the ability to initiate both direct and cross-presentation of epitopes to T cells. There are various pathways by which dendritic cells can process antigen, but the highest avidity T cell responses (i.e., the most potent) are generated if more than one pathway is used to present the same epitope. In the case of ImmunoBody®, the DNA form is taken up and processed directly by dendritic cells whereas the protein form (which is produced from the DNA in cells at the site of the injection) binds to the high affinity Fc receptor on dendritic cells leading to cross-presentation. As a result of both the direct and cross-presentation, the T cells not only have a higher avidity (up to 100-fold increased potency), but there are many more T cells generated against the epitopes of interest.
Compared to viral vector vaccines, Scancell notes the hesitancy around these over blood clot fears in these types; while noting that anti-vector immunity could emerge as a problem. “Multiple boosting for these virally-vector
Sanofi has agreed to buy U.S. biotech company Translate Bio in a $3.2 billion deal.
Paul Hudson, Sanofi Chief Executive Officer, said: “Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics.
http://www.pharmafile.com/news/584425/sanofi-buy-translate-bio-32-billion
“However, mRNA vaccines can only incorporate a single antigen – the inclusion of two antigens would require the development of a second, separate mRNA vaccine. DNA vaccines such as COVIDITY can accommodate multiple antigens in the same vaccine.”
“The inclusion of a single antigen in all of the currently authorised vaccines leaves open the possibility of escape from vaccine protection and the emergence of new viral variants.?
“Nucleic acid-based vaccines can be designed very quickly, which is why these were among the first COVID-19 vaccines to enter clinical trials. Both DNA and mRNA vaccines induce humoral as well as cellular immunity and are very safe as they are not associated with replicating microorganisms.
Compared to viral vector vaccines, Scancell notes the hesitancy around these over blood clot fears in these types; while noting that anti-vector immunity could emerge as a problem. “Multiple boosting for these virally-vectored vaccines will be limited by progressive boosting of anti-vector immunity and new variant adenovirus-based vaccines may not be feasible due to pre-existing vector immunity that is likely to abrogate responses against any new insertion.”?
DNA vaccines could also provide large-scale, low cost manufacture, with long-term stability and no need for ultra-cold storage, the company adds.
https://www.biopharma-reporter.com/Article/2021/08/02/Could-DNA-based-COVID-19-vaccine-offer-variant-busting-booster-shot
https://www.biopharma-reporter.com/Article/2021/08/02/Could-DNA-based-COVID-19-vaccine-offer-variant-busting-booster-shot
Could DNA-based COVID-19 vaccine offer variant-busting booster shot?
02-Aug-2021 By Rachel Arthur
With Scancell taking its DNA-based COVID-19 vaccine tech into clinical trials this year, it is already focusing its attention on the tech’s potential to be used as a needle-free booster shot to address Variants of Concern.
Pfizer, which shares profits with its German partner BioNTech, expects to raise prices after the pandemic is over.
https://www.ft.com/content/d415a01e-d065-44a9-bad4-f9235aa04c1a
As I said before, If a Mers type version of the Coronavirus that spreads much better than Mers did , then Covidity (If it works) would suddenly become very popular.
The likelihood of that happening anytime soon is very low but a vaccine covering variants would be very popular and a security against Mers 2.
https://news.sky.com/story/covid-19-new-deadlier-coronavirus-variant-a-realistic-possibility-sage-warns-12368798
The emergence of a new COVID variant with a similar death rate to MERS, which kills one in three infected people, is a "realistic possibility", the government's scientific advisers have warned.
They considered a scenario where a variant causes severe disease in a greater proportion of the population than has previously occurred, with similar death rates to other coronaviruses SARS (10%) or MERS (35%).
https://wwwnc.cdc.gov/eid/article/26/2/19-0697_article
MERS-CoV is transmitted sporadically from dromedary camels to humans and occasionally through human-to-human contact.
DEADLINE FOR APPLICATIONS: 12 Midnight GMT 31 July 2021
Supervisors: James Dixon (School of Pharmacy), with Scancell (SME)
Development of an intradermal or inhaled DNA vaccine for COVID-19 and beyond
Intradermal and inhaled delivery of nucleic acid vaccines could be clinically effective, safe and globally-deployable against multiple complex diseases. This project will aim to combine physical and peptide-based delivery systems to enhance the efficacy and application of such technologies to the COVID-19 vaccine (‘Covidity’) presently under-development by our consortium (funded by Innovate-UK). This PhD will formulate and test combined systems for skin and lung-focused vaccine delivery in ex vivo tissue models, then move to rodent models, examining virus neutralisation, T cell responses and protection in virally challenged animals. The platform technology optimised and demonstrated will have wide ranging impact on future applications of nucleic acid vaccine approaches (including DNA, mRNA and oligo-based methods). The PhD will also directly aid attempts to translate antibody and peptide-engineering knowhow to generate a rapidly deployable and safe immunisation system for multiple complex diseases
https://www.scancell.co.uk/modi-2
The Modi-2 vaccine exploits a second post-translational modification, stimulating the production of CD4 T cells using tumour-associated peptide epitopes in which the lysine residues are converted to homocitrulline. This change occurs via a process known as carbamylation, leading to a change in molecular charge which, in turn, alters antigenic properties and can result in the generation of unique T cell epitopes.
Scancell has identified homocitrullinated epitopes derived from several proteins, including vimentin, aldolase, cytokeratin 8, immunoglobulin binding protein (BiP), nucleophosmin (NPM), a-enolase, ß-catenin and heat shock protein (HSP-60), all of which generate potent T cell responses in preclinical models. Evidence exists for all of these proteins having a link to a wide range of cancer types:
Smokers have increased serum thiocyanate levels which drives homocitrullination and increases the risk of autoimmune disease, but this potentially also provides a target for vaccination.
The vaccine was very effective (90% survival) as the induced CD4 T cells directly targeted the homocitrullinated tumor and likely reversed the immunosuppressive environment.
Conclusion We propose that MPO, potentially produced by MDSCs, catalyzes the buildup of cyanate in the TME which diffuses into tumor cells causing homocitrullination of cytoplasmic proteins which are degraded and, in the presence of IFN?, presented by MHC-II for direct CD4 T-cell recognition. Homocitrullinated proteins are a new target for cancer vaccines and may be particularly effective against tumors containing high levels of MPO expressing MDSCs.
https://jitc.bmj.com/content/9/7/e001910